Full Press Release Details
REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Guggenheim Healthcare Innovation Conference
Date: Monday, November 11, 2024
Event: Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Event: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.
LifeSci Advisors, LLC